Use of letermovir for cytomegalovirus primary prophylaxis in lung transplant recipients

被引:0
|
作者
Kleiboeker, Hanna L. [1 ]
Wang, Jacob [2 ]
Borkowski, Nicole [3 ]
Miner, Brad [3 ]
Prom, Alyson [1 ]
Paplaczyk, Krista [1 ]
Wright, Jennifer [3 ]
Subramani, Mrinalini Venkata [4 ]
Arunachalam, Ambalavanan [4 ]
Betensley, Alan D. [4 ]
Tomic, Rade [4 ]
Myers, Catherine N. [4 ]
机构
[1] Northwestern Mem Hosp, Dept Pharm, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[3] Northwestern Mem Hosp, Canning Thorac Inst, Dept Transplant Pulmonol, Div Pulm & Crit Care, Chicago, IL USA
[4] Northwestern Univ, Feinberg Sch Med, Dept Transplant Pulmonol, Div Pulm & Crit Care, Chicago, IL USA
关键词
solid organ transplant; lung transplant; cytomegalovirus; myelosuppression; REPLICATION;
D O I
10.1111/tid.14337
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Cytomegalovirus (CMV) is a driver of negative outcomes after lung transplant (LTX) and primary prophylaxis (PPX) with valganciclovir (VGC) is standard-of-care. VGC is associated with myelosuppression, prompting interest in letermovir (LTV). Methods: Adults receiving LTX between April 1, 2015, and July 30, 2022, at our institution were evaluated. Patients were excluded if low CMV risk (D-/R-), survived <90 days post-LTX, or transferred care before PPX withdrawal. Primary outcomes were leukopenia (white blood cell count [WBC] <= 3.0 x 10(9)/L), severe leukopenia (WBC <= 2.0 x 109/L), and neutropenia (absolute neutrophil count <= 1500 cells/<mu>L) requiring granulocyte-colony stimulating factor (GCSF) on PPX. Secondary outcomes included breakthrough CMV infection and post-PPX CMV infection. Results: 204 patients met inclusion criteria: 175 patients on VGC and 29 patients on LTV (after VGC conversion). Most patients received bilateral LTX (62.7%) with non-lymphocyte-depleting induction (96.6%) and moderate-risk serostatus (D+/R+, 48.5%). Patients transitioned from VGC to LTV after a mean of 178 days (SD 80.8 days) post-transplant. Patients on VGC experienced significantly more leukopenia (82.3% vs. 58.6%, p = 0.008), severe leukopenia (57.1% vs. 31.0%, p = 0.016), and neutropenia requiring GCSF (70.9% vs. 51.7%, p = 0.048). Breakthrough (5.7% vs. 3.4%, p = 0.955) and post-PPX (24.6% vs. 37.9%, p = 0.199) infections were similar. A subgroup analysis of patients with high-risk serostatus showed similar trends, though did not reach statistical significance. Conclusions: In this single-center study, the incidence of leukopenia and neutropenia requiring GCSF were reduced with LTV compared to VGC. Breakthrough and post-PPX infections were not significantly different. This evidence suggests that LTV has comparable efficacy with reduced myelosuppression compared to VGC in LTX recipients, and may be an appropriate alternative for PPX. image
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Cytomegalovirus prophylaxis with IV ganciclovir in lung transplant recipients: The long and the short of it!
    Orens, JB
    [J]. CHEST, 1999, 116 (05) : 1152 - 1153
  • [42] CMV REACTIVATION AFTER STOPPING LETERMOVIR PRIMARY PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS
    Chavaz, Lara
    Royston, Lena
    Masouridi-Levrat, Stavroula
    Mamez, Anne-Claire
    Giannotti, Federica
    Morin, Sarah
    Van Delden, Christian
    Chalandon, Yves
    Neofytos, Dionysios
    [J]. BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 93 - 93
  • [44] CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
    Chavaz, Lara
    Royston, Lena
    Masouridi-Levrat, Stavroula
    Mamez, Anne-Claire
    Giannotti, Federica
    Morin, Sarah
    Van Delden, Christian
    Chalandon, Yves
    Neofytos, Dionysios
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (04):
  • [45] Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients A Randomized Clinical Trial
    Limaye, Ajit P.
    Budde, Klemens
    Humar, Atul
    Vincenti, Flavio
    Kuypers, Dirk R. J.
    Carroll, Robert P.
    Stauffer, Nicole
    Murata, Yoshihiko
    Strizki, Julie M.
    Teal, Valerie L.
    Gilbert, Christopher L.
    Haber, Barbara A.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (01): : 33 - 42
  • [46] Cytomegalovirus Antiviral Resistance Among Kidney Transplant Recipients in a Phase 3 Trial of Letermovir vs Valganciclovir Prophylaxis
    Strizki, Julie M.
    Diamond, Tracy L.
    Teal, Valerie L.
    Gilbert, Christopher L.
    Wang, Weiwen
    Stauffer, Nicole
    Haber, Barbara A.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2024,
  • [47] Letermovir Prophylaxis for Cytomegalovirus REPLY
    Marty, Francisco M.
    Maertens, Johan
    Badshah, Cyrus
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (10): : 965 - 965
  • [48] EFFECTIVENESS OF LETERMOVIR FOR CYTOMEGALOVIRUS PROPHYLAXIS IN SEROPOSITIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A GLOBAL SYSTEMATIC REVIEW
    Sepassi, A.
    Saunders, I
    Bounthavong, M.
    Watanabe, J.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S322 - S322
  • [49] Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients
    Wreghitt, TG
    Abel, SJC
    McNeil, K
    Parameshwar, J
    Stewart, S
    Cary, N
    [J]. TRANSPLANT INTERNATIONAL, 1999, 12 (04) : 254 - 260
  • [50] Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies
    Vyas, Ami
    Raval, Amit D.
    Kamat, Shweta
    LaPlante, Kerry
    Tang, Yuexin
    Chemaly, Roy F.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (01):